Modeling antibody persistence after MenACYW-TT vaccination and comparative analysis with other quadrivalent meningococcal vaccines

Abstract

Abstract Evaluating the persistence of antibody titers produced by quadrivalent meningococcal vaccines is crucial for determining the optimal timing for primary and booster doses. Using 3 − 7-year persistence data after a single priming dose of MenACYW-TT to fit a statistical model of antibody decay over time (10 years), this analysis modeled long-term antibody persistence for this vaccine in toddlers (12–23 months), adolescents/young adults (13–26 years), and older adults (≥ 56 years), comparing it with other vaccines (MCV4-TT, MenACWY-CRM, MPSV4). The statistical model is based on a Bayesian approach and it accounts for vaccine- and age group-specific antibody decline, missing data, assay errors, and antibody boosting from breakthrough infections. At 10 years post-vaccination, it predicted comparable or higher seroprotective immunopersistence for MenACYW-TT (titers ≥ 1:8 with hSBA) versus (1) MCV4-TT in toddlers (77% [95% CI 70–84] vs. 17% [6–31] for serogroup C, 67% [59–74] vs. 36% [20–53] for serogroup W); (2) MenACWY-CRM in adolescents/young adults (63% [55–71] vs. 40% [32–48] for serogroup C, 67% [59–74] vs. 57% [47–67] for serogroup W); and (3) MPSV4 in older adults (31% [23–39] vs. 22% [14–29] for serogroup C, 38% [31–46] vs. 20% [14–27] for serogroup W). In conclusion, our analysis indicated similar or higher immune persistence at 10 years for MenACYW-TT compared with other quadrivalent meningococcal vaccines, particularly for serogroups C and W.